^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Small Lymphocytic Lymphoma |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) + Gazyva (obinutuzumab) (CD20 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma…FIRST-LINE THERAPY…Preferred regimens…Venetoclax + obinutuzumab (category 1)…
